President & CEOOfficers of the CorporationBoard of TrusteesFoundation BoardLeadership CouncilAbout Joslin ResearchAdvocacy & Gov't AffairsHistory
Newly DiagnosedManaging DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsJoslin Clinical ResearchInfo for Healthcare ProfessionalsJoslin Clinical Guidelines
Make an AppointmentAdult ClinicYoung Adult Transition CarePediatricsEye CareWeight Management ProgramsDO ITMental Health & CounselingReferring PhysiciansBillingAfrican American ProgramsAsian ClinicLatino Diabetes InitiativeAbout Joslin ResearchVolunteer for Clinical Research StudiesInfo for Healthcare ProfessionalsClinical Guidelines
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside Joslin
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCause MarketingHealthcare ProfessionalsCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

News Release

Joslin Diabetes Center Introduces Joslin Institute for Technology Translation (JITT)

Dexcom, Inc. signs on as first JITT Founding Member

BOSTON (June 10, 2014) – Joslin Diabetes Center today announced the introduction of the Joslin Institute for Technology Translation (the “Institute” or JITT), a new division of Joslin Diabetes Center that formalizes the delivery of Joslin’s clinical solutions to medical device and technology companies. In addition, it was announced that Dexcom, Inc., a San Diego-based maker of continuous glucose monitoring systems for patients and blood glucose monitoring systems for healthcare providers in hospital settings, has joined to become the first Founding Member of the JITT and is a member of the Institute’s Advisory Board.

“Our goal in establishing the Joslin Institute for Technology Translation is to further the use and development of technology and medical devices to improve diabetes care, improve the lives of those living with diabetes and reduce health care costs,” said John L. Brooks III, President and CEO of Joslin Diabetes Center.  “With Joslin’s expertise as the world's largest diabetes research and clinical care organization, the Institute is uniquely positioned to impact digital health by offering meaningful solutions to strengthen technology, and we are extremely pleased to have an organization of Dexcom’s caliber join us in this quest.”

The mission of the Joslin Institute for Technology Translation will focus on four key areas:

  • Create and offer physician-designed, and patient-tested, decision support tools for improved solutions in glucose and insulin management;
  • Be a powerful voice in moving digital health to improve diabetes care in a cost-effective approach – collaborating with numerous medical device and technology organizations;
  • Create individualized, confidential collaborations with industry partners providing new solutions that advances the monitoring and treatment of diabetes via new technologies; and
  • Pioneer innovative education and training programs that optimize decision-making processes and the adoption of best-in-class technologies for healthcare professionals and patients world-wide.

“Dexcom is honored to join as the premiere partner with the Joslin Institute for Technology Translation, collaborating to share best medical practices and advanced technological innovations for patients with diabetes and the health care practitioners who treat them,” said Terrance H. Gregg, CEO of Dexcom. “Daily management of diabetes is imperative, and Dexcom continues its commitment to effective diabetes management through our new role in partnership with Joslin’s Institute.”

“The value of using technology to improve patient care with a chronic condition like diabetes cannot be overstated, “ said Howard Wolpert, M.D., director of JITT. “I look forward to working with our partners, starting with Dexcom, to make clinical recommendations to significantly compliment technology for improved patient care on a worldwide basis.”

Joslin Diabetes Center does not promote or endorse any product. Revenue and fees from the JITT will be invested in digital health to improve patient care.